Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11174975 | 0.86 | MEN1 (0.42) | EPHX1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL30185875 | 0.84 | L3MBTL1 (0.47) | MEN1KMT2AL3MBTL1NPSR1HPGD | |
| SCHEMBL27471665 | 0.84 | MEN1 (0.41) | EPHX1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL1835772 | 0.84 | L3MBTL1 (0.47) | MEN1KMT2AL3MBTL1NPSR1HPGD | |
| SCHEMBL3342292 | 0.83 | EPHX1 (0.53) | EPHX1L3MBTL1CYP4F2CYP4A11APOBEC3G | |
| SCHEMBL11712958 | 0.82 | MEN1 (0.39) | EPHX1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL28349710 | 0.82 | MEN1 (0.39) | EPHX1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL4193615 | 0.82 | MEN1 (0.39) | EPHX1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL28299708 | 0.82 | MEN1 (0.39) | EPHX1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL1395495 | 0.82 | EPHX1 (0.51) | EPHX1MEN1KMT2AL3MBTL1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116102521-A | Multifunctional prodrug delivery compound based on in-vivo active oxygen response, preparation method and application | 西安交通大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-114891053-A | Compositions comprising reversibly modified oligonucleotides and uses thereof | 迪克纳制药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-109890207-B | Compositions comprising reversibly modified oligonucleotides and uses thereof | 迪克纳制药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-109890207-A | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | 迪克纳制药公司 | 2019-06-14 | — | — | CN | disclosed |
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2008118784-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | TARGANTA THERAPEUTICS CORP. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | EPHX1 2899/4885MEN1 3682/4885KMT2A 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.